The Patent Lawyer
NewsThe latest IP news – to join our panel of Patent news correspondents, please contact us
Wi-Fi 7 Patent Landscape Report
Who is really leading the Wi-Fi 7 patent landscape? Wi-Fi 7 is rapidly moving toward widespread adoption, bringing a new generation of SEP licensing, portfolio, and litigation considerations. Insight IP’s latest research identifies 2,507 active, granted patent...
Drug Repurposing & Repositioning: Turning Scientific Opportunity into Commercial Reality
New Insight IP Boardroom Series Report | September 2026 Drug repurposing offers an attractive proposition: identifying new therapeutic uses for existing pharmaceutical compounds can reduce development timelines, leverage established safety data and lower some of the...
Australian generics turn preliminary discovery into patent validity tool
Generic drug companies are using preliminary discovery in Australia to investigate whether they have grounds to challenge the validity of pharmaceutical patents, in a potentially significant development for patent litigation strategy. The issue arose in proceedings...
Anaqua study finds AI is redefining semiconductor innovation
The semiconductor industry is being transformed, and artificial intelligence (AI) is the driver. Anaqua, a leading provider of innovation and intellectual property (IP) management technology and services, today released key findings from its 2026 Semiconductor...
Trinidad and Tobago highlights changes to IP enforcement rules for imported goods
The Intellectual Property Office has published a notice concerning government amendments to the Intellectual Property Rights (Imported Goods) Enforcement Rules, with particular implications for patent enforcement at the border. Trinidad and Tobago's Intellectual...
Optis v. Apple: what the Federal Circuit’s decision means for functional claiming
The Federal Circuit's June 16, 2025, decision in Optis Cellular Technology, LLC v. Apple Inc., 2025 US App. LEXIS 14745 shines a renewed spotlight on a recurring challenge in patent law: functional claiming. Specifically, it reaffirms the court's willingness to apply...
Delhi High Court denies AbbVie’s anti-cMet ADC patent
This article discusses an appeal filed by AbbVie Biotherapeutics Inc. and AbbVie Inc. (Appellants) at the Delhi High Court against the refusal of their patent application (Application No. 201817047767) for an anti-cMet antibody-drug conjugate by the Assistant...
UPC and EPO diverge on inventive step: lessons from Amgen’s PCSK9 patent battle
In a landmark test of the new Unified Patent Court (UPC), the European patent landscape faces a striking divergence between the UPC and the European Patent Office (EPO) on the issue of inventive step. The dispute centers on Amgen's European patent EP 3 666 797, which...
Therapeutic efficacy is a must for a novel intermediate compound to overcome Section 3(d) objection
In an appeal case between Zeria Pharmaceutical Co. Ltd., v. The Controller of Patents (C.A.(COMM.IPD-PAT) 452/2022) before the Delhi High Court, wherein the appellant - a Japanese Corporation - filed an Indian Patent Application, numbered 3630/DLNP/2011 (the subject...
Should translation requirements apply equally in patent law?
A recent High Court judgment in India highlights a potential procedural fairness question in patent examination regarding English translation standards. While patent applicants face rigorous translation requirements under multiple Patent Rules, with severe...
UPC validates second medical use patent in Sanofi v. Amgen antibody therapeutics ruling, finds non-infringement
The Düsseldorf Local Division of the Unified Patent Court (UPC) has handed down a key decision in UPC CFI 505/2024, affirming the validity of a second medical use patent owned by Regeneron and licensed to Sanofi. The case involved alleged infringement by Amgen’s PCSK9...
Annual Report 2024 of the Boards of Appeal of the European Patent Office
The Annual Report 2024 of the Boards of Appeal of the European Patent Office has been published today. It is available in English, German, and French on the Boards' website. Delivering decisions of the highest quality continued to be a central priority in 2024. As in...
Certainty for businesses and choice for consumers as UK maintains IP rights regime
No legislative changes mean businesses can continue operating under the existing exhaustion of intellectual property rights regime without any new requirements. The UK+ regime protects creators and innovators while ensuring fair competition in the marketplace and...
Crystal Crop v. Safex: Delhi High Court on Doctrine of Equivalents and prosecution history estoppel in patent disputes
In Crystal Crop Protection Ltd. v. Safex Chemicals India Ltd. & Ors., CS(COMM) 196/2024, Neutral Citation: 2025:DHC:3382, decided on May 7, 2025 by Hon’ble Mr Justice Amit Bansal of the Delhi High Court, the court refused to grant an interim injunction, holding...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.











